meta|Evidence - COVID-19
click on circles to display study description...
Comirnaty (tozinameran - Pfizer/BIONTECH) (n=1528) vs. placebo (n=757)
randomized controlled trial risk of bias NA
BNT162b2 vaccine (2 doses)
Intramuscular (deltoid) injection of two doses of BNT162b2 administered 21 days apart at the dose level selected during phase 1 (10μg).
Placebo (2 doses)
Intramuscular (deltoid) injection of two doses of saline placebo administered 21 days apart.
COVID-19 prophylaxis (children)
Children with no or stable preexisting conditions were eligible to participate, except those with an immunocompromising or immunodeficiency disorder, those with a history of MIS-C, or those receiving immunosuppressive therapy (including cytotoxic agents and systemic glucocorticoids).
Double-blind.
81 sites in the United States, Spain, Finland, and Poland.
Phase 2-3.
Comirnaty (tozinameran - Pfizer/BIONTECH) (n=1134) vs. placebo (n=1130)
randomized controlled trial some concerns about risk of bias
BNT162b2
Two intramuscular injections of 30 μg of BNT162b2 21 days apart.
placebo
Two intramuscular injections of 30 μg of placebo (saline) 21 days apart.
COVID-19 prophylaxis (children)
double-blind
multinational
Nuvaxovid (NVX-CoV2373) Novavax (n=-9) vs. placebo (n=-9)
randomized controlled trial risk of bias NA
placebo
COVID-19 prophylaxis (children)
single blind
USA, 73 sites
Spikevax (Moderna mRNA-1273 COVID-19 vaccine) (n=2489) vs. placebo (n=1243)
randomized controlled trial some concerns about risk of bias
Two vaccinations of mRNA-1273 given 28 days apart
Each injection containing 100 μg, for a total dose of 200 μg, 28 days apart.
Placebo
Two doses 28 days apart.
COVID-19 prophylaxis (children)
Double-blind.
26 sites in the United States.
Phase 2-3.
Spikevax (Moderna mRNA-1273 COVID-19 vaccine) (n=3005) vs. placebo (n=997)
randomized controlled trial risk of bias NA
two dose s of mRNA-1273 given 28 days apart
selected dose during part 1
placebo
COVID-19 prophylaxis (children)
double blind
US, Canada
powered by vis.js Network